A Phase 2a, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Infection.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs BIT 225 (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Biotron
- 17 Mar 2016 According to Biotron media release, the company aims to presented details data from this trial at a scientific conference in 2016.
- 17 Mar 2016 Results published in a Biotron media release.
- 01 May 2013 Further results presented at the International Liver Congress 2013, according to a Biotron media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History